

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

Conference Call and Webcast at 8:30AM Eastern Time

NEW YORK, May 2, 2024 /PRNewswire/ -- **Lucid Diagnostics Inc. (Nasdaq: LUCD)** ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Monday, May 13, 2024, at 8:30 AM ET. During the call, [Lishan Aklog, M.D.](#), Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, [Dennis McGrath](#), Lucid's Chief Financial Officer, will discuss the Company's first quarter 2024 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool for at-risk patients to mitigate the risks of cancer and cancer deaths through early detection of esophageal precancer.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

SOURCE Lucid Diagnostics

For further information: Matt Riley, PAVmed and Lucid Diagnostics, 610.348.8926, mjr@pavmed.com

<https://ir.pavmed.com/2024-05-02-Lucid-Diagnostics-to-Hold-a-Business-Update-Conference-Call-and-Webcast-on-May-13.-2024>